* PAT grows by 11% in FY2011
* Shelcal K and Shelcal HD gaining traction
* Completes NCD program of Rs. 118.80 Cr and Rs. 73.00 Cr in two separate Tranches
* Launches I-Vit Plus; Launches Somazina Plus

Mumbai, India, May 11, 2011 — Elder Pharmaceuticals Ltd (NSE- ELDERPHARM) ( http://www.elderindia.com ) an integrated pharmaceuticals company headquartered in Mumbai has posted robust results for the fourth quarter ended March 2011 (Q4 FY2011). As per the consolidated unaudited provisional results taken on record on May 10th, 2011, the income from operations has gone up to Rs 3,027.14 Crore for Q4-FY2011 as compared to Rs. 1,896.94 Crore during the corresponding quarter in the previous year. The consolidated operating profit (PBIDT) too has gone up to Rs. 523.52 Crore for Q4 FY2011 reflecting a growth of 40% over the previous corresponding quarter’s figure of Rs. 374.86 Crore. The consolidated Net Profit for Q4 FY2011 stood at Rs. 172.76 Crore. The consolidated EPS on a non – annualized basis stood at Rs. 8.41 for Q4 FY2011 and at Rs. 30.03 for FY2011.

For the twelve months ended March 2011, the unaudited consolidated sales turnover is Rs. 9,592.03 Cr (previous 12 months- Rs. 7,208.98 Cr – audited) up by 33% and the unaudited Net Profit is Rs. 616.76 Cr (previous 12 months – Rs 553.92 Cr – audited) up by 11%.

During the quarter under review, the Company completed its NCD raising program to augment medium to long term resources including regular capital expenditure. First tranche of Rs. 118.80 Crore and Second Tranche of Rs. 73.00 Crore were completed on 23rd Dec’2010 and 31st March 2011 respectively.

The Company launched I-Vit Plus and Somazina Plus during the quarter under review.

* I-Vit Plus is a blend of micro-nutrients helpful in providing adequate mineral/vitamin and essential nutrient supplementation for correcting suboptimal vitamin/mineral intake.

* Somazina Plus is a unique combination of Citicholine with Piracetam that improves brain function and stimulates the central nervous system thus offering neuroprotection and enhancing cognition.

Elder Pharmaceuticals has presence in niche therapeutic segments like Women’s healthcare, Wound care, Nutraceuticals /vitamin Supplements, Cardiology, Diabetes, Dermatology, Antibiotics and neurology. It is the market leader in calcium supplements (Shelcal), wound healing and injectable B12 vitamin. The company has a judicious mix of drug formulations, and active pharma ingredients (APIs). It has 6 manufacturing plants in India located in Maharashtra, Uttarakhand & Himachal Pradesh. The company has a state-of-the-art Research & Development Centre at Navi Mumbai which is recognized by the Department of Scientific & Industrial Research, Ministry of Science & Technology. ( http://www.elderindia.com ).

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com

* Alliances, Acquisitions and higher Domestic demand add to the company’s topline.
* Successful fund raising of Rs 69.70 Cr through Qualified Institutional Placement (QIP) route.

Mumbai, India, November 13, 2010 — Elder Pharmaceuticals Ltd (NSE- ELDERPHARM) an integrated pharmaceuticals company ( http://www.elderindia.com ) headquartered in Mumbai has posted excellent results for the second quarter ended Sep 2010 (Q2 FY2011). As per the consolidated unaudited provisional results taken on record on November 12, 2010, the income from operations has gone up to Rs 210.65 Crore for Q2 FY2011 as compared to Rs. 174.95 Crore during the corresponding quarter in the previous year. The consolidated operating profit (PBIDT) too has gone up to Rs 41.89 Crore for Q2 FY2011 reflecting a growth of 43% over the previous corresponding quarter’s figure of Rs 29.37 Crore. The consolidated Net Profit too has gone up to Rs 13.68 Crore (previous year’s quarter – Rs 9.30 Crore) – a spurt of 47%. The consolidated EPS on a non – annualized basis comes to Rs 7.20.

For the half year ended Sept 2010, the consolidated sales turnover is Rs 404.95 Cr (previous half year – Rs 344.92 Cr) up by 17% and the net profit is Rs 30.36 Cr (previous half year – Rs 18.90 Cr) up by 61%.

During the quarter under review, Elder ( http://www.elderindia.com ) successfully raised funds to the tune of Rs 69.70 Crore through the Qualified Institutional Placement (QIP) route. The company also hiked stake in its Bulgarian subsidiary ‘Biomeda’ to 92.2%. The various international alliances of the company, commissioning of Langa Road facility, launch of new products, penetration into Rural & Semi-Urban markets and strong growth in the traditional products have contributed to the company’s better working.

Elder Pharmaceuticals has presence in niche therapeutic segments like Women’s healthcare, Wound care, Nutraceuticals /vitamin Supplements, Cardiology, Diabetes, Dermatology, Antibiotics and neurology. It is the market leader in calcium supplements (Shelcal), wound healing and injectable B12 vitamin. The company has a judicious mix of drug formulations, and active pharma ingredients (APIs). It has 6 manufacturing plants in India located in Maharashtra, Uttarakhand & Himachal Pradesh. The company has a state-of-the-art Research & Development Centre at Navi Mumbai which is recognized by the Department of Scientific & Industrial Research, Ministry of Science & Technology. (http://www.elderindia.com).

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
mitesh@publicrelationindia.com
http://www.publicrelationindia.com
http://www.elderindia.com